Danaher Corporation DHR
Healthcare · Diagnostics & Research · United States · S&P 500
Based on the available data, Danaher Corporation gets an algorithmic score of 59/100. It trades at 226.11 $, with a bullish technical trend (RSI 68.8) and 31.3% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- Meaningful dividend (71.00%).
Weaknesses
- Shrinking revenue (-2.7% per year).
Fundamentals
| P/E | 40.52 |
| Forward P/E | 24.31 |
| PEG | 1.32 |
| P/B | 3.02 |
| EV/EBITDA | 22.73 |
| P/S | 6.33 |
| ROE % | 7.61 |
| ROA % | 3.95 |
| Gross margin % | 58.75 |
| Operating margin % | 19.78 |
| Net margin % | 15.95 |
| Revenue growth % (y/y) | 5.50 |
| Earnings growth % (y/y) | 59.70 |
| Revenue CAGR % | -2.67 |
| Earnings CAGR % | -20.56 |
| Debt/Equity % | 52.97 |
| Current ratio | 1.65 |
| FCF yield % | 3.31 |
| Dividend yield % | 71.00 |
| Payout % | 25.67 |
Returns
| 1 month | +4.7 % |
| 3 months | +18.7 % |
| 6 months | +23.2 % |
| YTD | -1.4 % |
| 1 year | +23.0 % |
| 3 years | +4.5 % |
| 5 years | -19.5 % |
Risk
| 1-year volatility | 31.3 % |
| Beta | 0.78 |
| 5-year max drawdown | -43.3 % |
| Sharpe 1A | 0.69 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.